N@N

Diamyd Medical to Nasdaq OMX Stockholm Mid Cap

^{Published on 2010-12-17 01:20:55 - Market Wire}
 

STOCKHOLM, Sweden--([ BUSINESS WIRE ])--Regulatory News:

DIAMYD MEDICAL AB (Pink Sheets:DMYDY)(STO:DIAMB):

Nasdaq OMX Stockholm has decided to move Diamyd Medical (DIAM B) from the Small Cap list to the Mid Cap list. The change is effective as of January 3, 2011. The Mid Cap segment includes companies with a market capitalization of between EUR 150 million and EUR 1 billion.

About Diamyd Medical

Diamyd Medical is a Swedish pharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and pain. The Diabetes business area consists of the antigen-based candidate drug DiamydŽ for the treatment and prevention of autoimmune diabetes. Phase III studies of DiamydŽ are currently in progress in Europe and the US. In 2010 the Company signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., for the development and commercialization of DiamydŽ. The Pain business area consists of development projects that use the Company's proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat chronic pain. A Phase I study of the candidate drug NP2 Enkephalin for cancer pain is ongoing, and the Company plans to initiate a Phase II study.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: [ www.diamyd.com ].

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.

Diamyd Medical AB (publ.)

Karlavgen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68

E-mail: [ info@diamyd.com ]. VAT no: SE556530-142001.

This information was brought to you by Cision [ http://www.cisionwire.com ]